{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:15:49Z","timestamp":1778170549133,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002825","name":"Dystrophic Epidermolysis Bullosa Research Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with epidermolysis bullosa (EB) are susceptible to development of squamous cell carcinomas (SCC) at sites of chronic inflammation and fibrosis. While triterpenoids such as RTA 408 (Omaveloxolone) have been shown to reduce inflammation and inhibit tumour growth in various cancer models, the utility of this class of drugs in the treatment of SCC has not been investigated. Given the dual anti\u2010inflammatory and anti\u2010neoplastic properties of triterpenoids, we hypothesized RTA 408 would be an effective treatment for SCCs that arise in the chronic inflammatory setting in EB. We tested the effects of topical RTA 408 on a mouse model of non\u2010Herlitz, junctional EB. RTA 408\u00a0significantly reduced phenotypic severity in the affected ears of Lamc2<jats:italic>jeb<\/jats:italic> mice. In cultures, RTA 408 reduced cell viability in EB\u2010associated SCC cell lines and normal human epidermal keratinocytes. When administered in vivo, RTA 408 inhibited SCC tumour growth in mice without cutaneous or systemic toxicity. These results suggest that RTA 408 can be a promising new therapy to reduce inflammation and inhibit SCC growth in patients with EB.<\/jats:p>","DOI":"10.1111\/exd.14564","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:21:44Z","timestamp":1647235304000},"page":"1083-1088","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-7159","authenticated-orcid":false,"given":"Adam J.","family":"Cohen\u2010Nowak","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily D.","family":"Correia","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla P.","family":"Portocarrero","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"South","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010020\u20100210\u20100"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225707"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.035"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103875"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13979"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12774"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14104"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920112798868719"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607160200"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201004\u20104539"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201014\u20100354"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201063482\u2010x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1667\/RR13900.1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476\u20104598\u201013\u201030"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25934"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.46"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aas9668"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin KY","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9030193"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.01.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.112.21.3641"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci34292"},{"issue":"5","key":"e_1_2_8_24_1","first-page":"3035","article-title":"CDDO\u2010me induces apoptosis and inhibits Akt, mTOR and NF\u2010kappaB signaling proteins in prostate cancer cells","volume":"27","author":"Deeb D","year":"2007","journal-title":"Anticancer Res"},{"issue":"1","key":"e_1_2_8_25_1","first-page":"31","article-title":"CDDO\u2010Me inhibits proliferation, induces apoptosis, down\u2010regulates Akt, mTOR, NF\u2010kappaB and NF\u2010kappaB\u2010regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells","volume":"7","author":"Deeb D","year":"2008","journal-title":"J Exp Ther Oncol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201009\u20103272"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S136992"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S193889"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14564","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/exd.14564","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T21:24:58Z","timestamp":1692653098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/exd.14564"],"URL":"https:\/\/doi.org\/10.1111\/exd.14564","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}